Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease

International Heart Journal

Volumn 46, Issue 4, 2005, Pages 647-656

  Ando, Jiro ^a   Kakishita, Mikio ^a   Sakai, Koyu ^a   Komura, Yasuo ^a   Nishiyama, Kei ^a   Iwabuchi, Masashi ^a   Yokoi, Hiroyoshi ^a   Yasumoto, Hitoshi ^a   Nosaka, Hideyuki ^a   Nobuyoshi, Masakiyo ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Class III antiarrhythmic agents; Ischemic heart disease; Nifekalant; Ventricular arrhythmia

Indexed keywords

HYPERTENSIVE AGENT; LIDOCAINE; MAGNESIUM SULFATE; NIFEKALANT; ANTIARRHYTHMIC AGENT; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ASSISTED CIRCULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FATALITY; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RISK ASSESSMENT; SURVIVAL RATE; TORSADE DES POINTES; TREATMENT OUTCOME; DRUG ADMINISTRATION; FEMALE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; MALE; MORTALITY; PATHOPHYSIOLOGY;

AGED; ANTI-ARRHYTHMIA AGENTS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PROGNOSIS; PYRIMIDINONES; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 33644874014     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.647     Document Type: Article

References (21)

1. Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. Cardiac arrest and resuscitation: A tale of 29 cities. Ann Emerg Med 1990; 19: 179-86.
2. Eisenberg MS, Cummins RO, Damon S, Larsen MP, Hearne TR. Survival rates from out-of-hospital cardiac arrest: Recommendations for uniform definitions and data to report. Ann Emerg Med 1990; 19: 1249-59.
3. Weaver WD, Copass MK, Bufi D, Ray R, Hallstrom AP, Cobb LA. Improved neurologic recovery and survival after early defibrillation. Circulation 1984; 69: 943-8.
4. Larsen MP, Eisenberg MS, Cummins RO, Hallstrom AP. Predicting survival from out-of-hospital cardiac arrest a graphic model. Ann Emerg Med 1993; 22: 1652-8.
5. Stults KR, Brown DD, Schug VL, Bean JA. Prehospital defibrillation performed by emergency medical technicians in rural communities. N Engl J Med 1984; 310:219-23.
6. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109: 157-63.
7. Kamiya J, Ishii M, Yoshihara K, Oyabe A, Banno H, Katakami T. MS-551: Pharmacological profile of a novel class III antiarrhythmic agent. Drug Dev Res 1993; 30:37-44.
8. Chen J, Komori S, Li B, Tamura K, Hashimoto K. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol 1996; 119: 937-42.
9. Martin DK, Nakaya Y, Wyse KR, Bursill JA, West PD, Campbell TJ. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. Pharmacol Toxicol 1995; 77: 65-70.
10. Nakaya H, Uemura H. Electropharmacology of nifekalant, a new class III antiarrythmic drug. Cardiovasc Drug Rev 1998; 16: 133-44.
11. Kondoh K, Hashimoto H, Nishiyama H, et al. Effects of MS-511, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994; 23: 674-80.
12. Tanabe T, Iwamoto T, Iwata O, et al. Electrophysiologic and blood-flow responses in the endocardium and epicardium to disopyramide and MS-511 during myocardial ischemia in the dog. J Cardiovasc Pharmacol 1999; 34: 275-86.
13. Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4301 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol 1996; 27: 159-66.
14. Hayashi H, Fujiki A, Tani M, Usui M, Inoue H. Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart. J Cardiovasc Pharmacol 1998; 31: 101-7.
15. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-92.
16. van Walraven C, Stiell JG, Wells GA, Hebert PC, Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. Ann Emerg Med 1998; 32: 544-53.
17. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-90.
18. Guidelines 2000 for Cardiopulumonary Resuscitation and Emergency Cardiovascular Care: An International Consensus on Science. 6. Advanced cardiovascular life support 5. Pharmacology I: Agents for arrhythmias. Circulation 2000; 102: Suppl I:I-112-28.
19. Takenaka K, Yasuda S, Miyazaki S, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J 2001; 65: 60-2.
20. Igawa M, Aonuma K, Okamoto Y, Hiroe M, Hiraoka M, Isobe M. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia. J Cardiovasc Pharmacol 2002; 40: 735-42.
21. Amino M, Yoshioka K, Iwata O, et al. Efficacy of nifekalant hydrochloride for life-threatening ventricular tachyarrhythimas in patients with resistance to lidocaine: A study of patients with out-of-hospital cardiac arrest. J Cardiol 2003; 41: 127-34.